This article from Issue 9 of the Analytix Reporter, produced by Merck, provides a simple, precise, and sensitive reversed-phase high performance liquid chromatography (RP-HPLC) gradient method for establishing traceability and total chromatographic analysis of dexamethasone.
/Merck_Analytix_Reporter/Issue%209/dexamethasone.png)
The given experimental conditions follow the USP43-NF38 monograph method for dexamethasone assay and organic impurity profiling. Baseline-resolved peaks were obtained for dexamethasone, betamethasone, dexamethasone acetate, and desoximetasone within 20 minutes with a Titan™ C18 UHPLC column (10 cm x 2.1 mm, 1.9 µm particles). This column has the same phase, length, and ID like in the monograph, but the packing is based on monodisperse particles with a slightly larger average particle size (1.9 µm), than referenced in the monograph (1.7 µm). The method was validated following the guidelines in USP General Chapters <621>, <1225>, and <1226>. The use of lower sample concentrations was compensated by a larger injection volume (to maintain mass on column) to improve reproducibility. The chromatographic separation was achieved using a mixture of 3.4 g/L monobasic potassium phosphate solution (pH 3.0) and acetonitrile as the mobile phase with gradient elution and UV detection at 240 nm. Although, comparatively a shorter relative retention time (RRT) was observed for dexamethasone acetate and desoximetasone, both the compounds showed an excellent chromatographic resolution (Rs > 10). Under the applied conditions, system suitability requirements are met, and the method demonstrates good selectivity, reproducibility, sensitivity, and accuracy.
For full experimental conditions and chromatographic data, download the full article.
To receive regular copies of the Analytix Reporter eNewsletter provide your email address below:
*The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.
